Plasma and Peritoneal Poly (ADP-Ribose) Polymerase Levels in Patients with Endometriosis
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sensky, T.; Liu, D. Endometriosis: Associations with menorrhagia, infertility and oral contraceptives. Int. J. Gynaecol. Obstet. 1980, 17, 573–576. [Google Scholar] [CrossRef] [PubMed]
- Houston, D.E. Evidence for the risk of pelvic endometriosis by age, race and socioeconomic status. Epidemiol. Rev. 1984, 6, 167–191. [Google Scholar] [CrossRef] [PubMed]
- Sourial, S.; Tempest, N.; Hapangama, D.K. Theories on the pathogenesis of endometriosis. Int. J. Reprod. Med. 2014, 2014, 179515. [Google Scholar] [CrossRef] [Green Version]
- Załęcka, J.; Pankiewicz, K.; Issat, T.; Laudański, P. Molecular Mechanisms Underlying the Association between Endometriosis and Ectopic Pregnancy. Int. J. Mol. Sci. 2022, 23, 3490. [Google Scholar] [CrossRef]
- Laudanski, P.; Charkiewicz, R.; Tolwinska, A.; Szamatowicz, J.; Charkiewicz, A.; Niklinski, J. Profiling of Selected MicroRNAs in Proliferative Eutopic Endometrium of Women with Ovarian Endometriosis. BioMed Res. Int. 2015, 2015, 760698. [Google Scholar] [CrossRef] [Green Version]
- Laudanski, P.; Szamatowicz, J.; Ramel, P. Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis. Gynecol. Endocrinol. 2005, 21, 106–110. [Google Scholar] [CrossRef]
- Laudański, P.; Szamatowicz, J.; Oniszczuk, M. Profiling of peritoneal fluid of women with endometriosis by chemokine protein array. Adv. Med. Sci. 2006, 51, 148–152. [Google Scholar] [PubMed]
- Laudanski, P.; Gorodkiewicz, E.; Ramotowska, B.; Charkiewicz, R.; Kuzmicki, M.; Szamatowicz, J. Determination of cathepsins B, D and G concentration in eutopic proliferative endometrium of women with endometriosis by the surface plasmon resonance imaging (SPRI) technique. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 169, 80–83. [Google Scholar] [CrossRef]
- Szamatowicz, J.; Laudański, P.; Tomaszewska, I.; Szamatowicz, M. Chemokine growth-regulated-alpha: A possible role in the pathogenesis of endometriosis. Gynecol. Endocrinol. 2002, 16, 137–141. [Google Scholar] [CrossRef]
- Laudanski, P.; Charkiewicz, R.; Kuzmicki, M.; Szamatowicz, J.; Świątecka, J.; Mroczko, B.; Niklinski, J. Profiling of selected angiogenesis-related genes in proliferative eutopic endometrium of women with endometriosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 172, 85–92. [Google Scholar] [CrossRef]
- Wróbel, M.; Wielgoś, M.; Laudański, P. Diagnostic delay of endometriosis in adults and adolescence-current stage of knowledge. Adv. Med. Sci. 2022, 67, 148–153. [Google Scholar] [CrossRef] [PubMed]
- Lebovic, D.I.; Mueller, M.D.; Taylor, R.N. Immunobiology of endometriosis. Fertil. Steril. 2001, 75, 1–10. [Google Scholar] [CrossRef]
- Karadadas, E.; Hortu, I.; Ak, H.; Ergenoglu, A.M.; Karadadas, N.; Aydin, H.H. Evaluation of complement system proteins C3a, C5a and C6 in patients of endometriosis. Clin. Biochem. 2020, 81, 15–19. [Google Scholar] [CrossRef]
- Koninckx, P.; Kennedy, S.; Barlow, D. Endometriotic disease: The role of peritoneal fluid. Hum. Reprod. Update 1998, 4, 741–751. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oosterlynck, D.J.; Cornillie, F.J.; Waer, M.; Vandeputte, M.; Koninckx, P.R. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil. Steril. 1991, 56, 45–51. [Google Scholar] [CrossRef]
- Blumenfeld, Z. Hormonal suppressive therapy for endometriosis may not improve patient health. Fertil. Steril. 2004, 81, 487–492. [Google Scholar] [CrossRef] [PubMed]
- Van Gorp, T.; Amant, F.; Neven, P.; Vergote, I.; Moerman, P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract. Res. Clin. Obstet. Gynaecol. 2004, 18, 349–371. [Google Scholar] [CrossRef]
- Vercellini, P.; Parazzini, F.; Bolis, G.; Carinelli, S.; Dindelli, M.; Vendola, N.; Luchini, L.; Crosignani, P.G. Endometriosis and ovarian cancer. Am. J. Obstet. Gynecol. 1993, 169, 181–182. [Google Scholar] [CrossRef]
- Swiersz, L.M. Role of endometriosis in cancer and tumor development. Ann. N. Y. Acad. Sci. 2002, 955, 281–292. [Google Scholar] [CrossRef]
- Brinton, L.A.; Gridley, G.; Persson, I.; Baron, J.; Bergqvist, A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am. J. Obstet. Gynecol. 1997, 176, 572–579. [Google Scholar] [CrossRef]
- Wyshak, G.; Frisch, R.E.; Albright, N.L.; Albright, T.E.; Schife, I. Reproductive factors and melanoma of the skin among women. Int. J. Dermatol. 1989, 28, 527–530. [Google Scholar] [CrossRef] [PubMed]
- Hornstein, M.D.; Thomas, P.P.; Sober, A.J.; Wyshak, G.; Albright, N.L.; Frisch, R.E. Association between endometriosis, dysplastic naevi and history of melanoma in women of reproductive age. Hum. Reprod. 1997, 12, 143–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ame, J.C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. Bioessays 2004, 26, 882–893. [Google Scholar] [CrossRef]
- Ray Chaudhuri, A.; Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 2017, 18, 610–621. [Google Scholar] [CrossRef]
- D’Amours, D.; Desnoyers, S.; D’Silva, I.; Poirier, G.G. Poly (ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem. J. 1999, 342, 249–268. [Google Scholar] [CrossRef]
- Kim, M.Y.; Zhang, T.; Kraus, W.L. Poly (ADP-ribosyl) ation by PARP-1:PAR-laying’NAD+ into a nuclear signal. Genes Dev. 2005, 19, 1951–1967. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reis, L.; Harada, H.; Wolchok, J.; Taniguchi, T.; Vilcek, J. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes. EMBO J. 1992, 11, 185–193. [Google Scholar] [CrossRef]
- Wang, C.; Du, M.; Huang, D.; Huang, K.; Huang, K. Inhibition of PARP1 Increases IRF-dependent Gene Transcription in Jurkat Cells. Curr. Med. Sci. 2019, 39, 356–362. [Google Scholar] [CrossRef]
- Hortu, I.; Ozceltik, G.; Karadadas, E.; Erbas, O.; Yigitturk, G.; Ulukus, M. The Role of Ankaferd Blood Stopper and Oxytocin as Potential Therapeutic Agents in Endometriosis: A Rat Model. Curr. Med. Sci. 2020, 40, 556–562. [Google Scholar] [CrossRef]
- Goławski, K.; Soczewica, R.; Kacperczyk-Bartnik, J.; Mańka, G.; Kiecka, M.; Lipa, M.; Warzecha, D.; Spaczyński, R.; Piekarski, P.; Banaszewska, B.; et al. The Role of Cadherin 12 (CDH12) in the Peritoneal Fluid among Patients with Endometriosis and Endometriosis-Related Infertility. Int. J. Environ. Res. Public Health 2022, 19, 11586. [Google Scholar] [CrossRef]
- Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss. Fertil. Steril. 2008, 90 (Suppl. S5), S60. [Google Scholar] [CrossRef] [PubMed]
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil. Steril. 1997, 67, 817–821. [CrossRef]
- Rahmioglu, N.; Fassbender, A.; Vitonis, A.F.; Tworoger, S.S.; Hummelshoj, L.; D’Hooghe, T.M.; Adamson, G.D.; Giudice, L.C.; Becker, C.M.; Zondervan, K.T.; et al. World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. Fertil. Steril. 2014, 102, 1233–1243. [Google Scholar] [CrossRef] [PubMed]
- Engvall, E.; Perlmann, P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971, 8, 871–874. [Google Scholar] [CrossRef]
- Van Weemen, B.K.; Schuurs, A.H. Immunoassay using antigen-enzyme conjugates. FEBS Lett. 1971, 15, 232–236. [Google Scholar] [CrossRef] [Green Version]
- Moonen, H.J.; Geraets, L.; Vaarhorst, A.; Bast, A.; Wouters, E.F.; Hageman, G.J. Theophylline prevents NAD+ depletion via PARP-1 inhibition in human pulmonary epithelial cells. Biochem. Biophys. Res. Commun. 2005, 338, 1805–1810. [Google Scholar] [CrossRef]
- Sarnaik, A.A.; Conley, Y.P.; Okonkwo, D.O.; Barr, T.L.; Fink, E.L.; Szabo, C.; Kochanek, P.M.; Clark, R.S. Influence of PARP-1 polymorphisms in patients after traumatic brain injury. J. Neurotrauma 2010, 27, 465–471. [Google Scholar] [CrossRef] [Green Version]
- Wani, W.Y.; Sunkaria, A.; Sharma, D.R.; Kandimalla, R.J.L.; Kaushal, A.; Gerace, E.; Chiarugi, A.; Gill, K.D. Caspase inhibition augments Dichlorvos-induced dopaminergic neuronal cell death by increasing ROS production and PARP1 activation. Neuroscience 2014, 258, 1–15. [Google Scholar] [CrossRef]
- Joshi, A.; Mahfooz, S.; Maurya, V.K.; Kumar, V.; Basanna, C.S.; Kaur, G.; Hanif, K.; Jha, R.K. PARP1 during embryo implantation and its upregulation by oestradiol in mice. Reproduction 2014, 147, 765–780. [Google Scholar] [CrossRef] [Green Version]
- Soni, U.K.; Chadchan, S.B.; Joshi, A.; Kumar, V.; Maurya, V.K.; Verma, R.K.; Jha, R.K. Poly(ADP-ribose) polymerase-2 is essential for endometrial receptivity and blastocyst implantation, and regulated by caspase-8. Mol. Cell Endocrinol. 2020, 518, 110946. [Google Scholar] [CrossRef]
- Imamura, T.; Neildez, T.M.; Thenevin, C.; Paldi, A. Essential role for poly (ADP-ribosyl)ation in mouse preimplantation development. BMC Mol. Biol. 2004, 5, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ménissier de Murcia, J.; Ricoul, M.; Tartier, L.; Niedergang, C.; Huber, A.; Dantzer, F.; Schreiber, V.; Amé, J.; Dierich, A.; LeMeur, M.; et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003, 22, 2255–2263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barreta, A.; Sarian, L.O.; Ferracini, A.C.; Costa, L.B.E.; Mazzola, P.G.; de Angelo Andrade, L.; Derchain, S. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis. Hum. Pathol. 2019, 85, 72–81. [Google Scholar] [CrossRef] [PubMed]
- Talebi, H.; Farahpour, M.R.; Hamishehkar, H. The effectiveness of Rutin for prevention of surgical induced endometriosis development in a rat model. Sci. Rep. 2021, 11, 7180. [Google Scholar] [CrossRef] [PubMed]
- Ekici, E.; Güney, M.; Nazıroğlu, M. Protective effect of cabergoline on mitochondrial oxidative stress-induced apoptosis is mediated by modulations of TRPM2 in neutrophils of patients with endometriosis. J. Bioenergy Biomembr. 2020, 52, 131–142. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Yuan, Y.; Ma, X.; Xing, F. Ca2+ channel subunit a 1D inhibits endometriosis cell apoptosis and mediated by prostaglandin E2. Ginekol. Polska 2019, 90, 669–674. [Google Scholar] [CrossRef] [Green Version]
- Ghabreau, L.; Roux, J.P.; Frappart, P.O.; Mathevet, P.; Patricot, L.M.; Mokni, M.; Korbi, S.; Wang, Z.-Q.; Tong, W.-M.; Frappart, L. Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. Int. J. Cancer 2004, 109, 317–321. [Google Scholar] [CrossRef]
Feature | Patients with Endometriosis (n = 47) | Patients without Endometriosis (n = 37) | p |
---|---|---|---|
Age [years] | 31.79 (SD ± 5.24) | 31.49 (SD ± 5.77) | 0.96 |
Day of menstrual cycle | 14.8 (SD ± 5.97) | 11.68 (SD ± 5.58) | 0.02 |
Stage I endometriosis | 13 (28%) | Not applicable | - |
Stage II endometriosis | 7 (15%) | Not applicable | - |
Stage III endometriosis | 15 (32%) | Not applicable | - |
Stage IV endometriosis | 10 (21%) | Not applicable | - |
Infertility | 28 (60%) | 19 (51%) | 0.51 |
Primary infertility | 23 (49%) | 13 (35%) | 0.27 |
Secondary infertility | 5 (11%) | 6 (16%) | 0.52 |
Endometrial ovarian cysts | 28 (60%) | Not applicable | - |
Mean PARP concentration [ng/L] | 1544.06 (SD ± 3455.73) | 1554.92 (SD ± 3250.36) | 0.73 |
Median PARP concentration [ng/L] | 442.7 (55.55–20360) | 451 (27.17–15390) |
Feature | Patients with Endometriosis (n = 48) | Patients without Endometriosis (n = 36) | p |
---|---|---|---|
Age [years] | 31.85 (SD ± 4.82) | 31.2 (SD ± 6.02) | 0.98 |
Day of menstrual cycle | 14.81 (SD ± 6.19) | 11.56 (SD ± 5.72) | 0.02 |
Stage I endometriosis | 15 (31%) | Not applicable | - |
Stage II endometriosis | 6 (13%) | Not applicable | - |
Stage III endometriosis | 17 (35%) | Not applicable | - |
Stage IV endometriosis | 9 (19%) | Not applicable | - |
Infertility | 19 (40%) | 21 (58%) | 0.12 |
Primary infertility | 18 (36%) | 17 (47%) | 0.38 |
Secondary infertility | 1 (2%) | 4 (11%) | 0.19 |
Endometrial ovarian cysts | 27 (56%) | Not applicable | - |
Mean PARP concentration [ng/L] | 760.2 (SD ± 676.78) | 646.73 (SD ± 647.56) | 0.61 |
Median PARP concentration [ng/L] | 451 (12.55–2219) | 294.15 (126.6–2391) |
Plasma PARP Concentrations [ng/L] | |||
Mean (±SD) | Median | p | |
Patients with endometriosis stages I and II (n = 20) | 2339.5 (±4746.14) | 830.35 (63.63–20,360) | 0.12 |
Patients with endometriosis stages III and IV (n = 25) | 960.33 (±2022.69) | 243.1 (55.55–10,180) | |
Patients with endometriosis stages I and II (n = 20) | 2339.5 (±4746.14) | 830.35 (63.63–20,360) | 0.44 |
Patients without endometriosis (n = 37) | 1554.92 (± 3250.36) | 451 (27.17–15,390) | |
Patients with endometriosis stages III and IV (n = 25) | 960.33 (±2022.69) | 243.1 (55.55–10,180) | 0.23 |
Patients without endometriosis (n = 37) | 1554.92 (± 3250.36) | 451 (27.17–15,390) | |
Peritoneal fluid PARP concentrations [ng/L] | |||
Patients with endometriosis stages I and II (n = 21) | 861.13 (±725) | 646.6 (12.55–2391) | 0.77 |
Patients with endometriosis stages III and IV (n = 26) | 700.18 (±644.82) | 451 (109.5–2219) | |
Patients with endometriosis stages I and II (n = 21) | 861.13 (±725) | 646.6 (12.55–2391) | 0.52 |
Patients without endometriosis (n = 36) | 646.73 (± 647.56) | 294.15 (126.6–2391) | |
Patients with endometriosis stages III and IV (n = 26) | 700.18 (±644.82) | 451 (109.5–2219) | 0.7 |
Patients without endometriosis (n = 36) | 646.73 (± 647.56) | 294.15 (126.6–2391) |
Plasma PARP Concentrations [ng/L] | |||
Mean (±SD) | Median | p | |
Patients with infertility (n = 47) | 2075.4 (±4149.94) | 1047 (55.55–20,360) | 0.04 |
Patients without infertility (n = 37) | 879.98 (±1731.04) | 213.2 (27.17–10,180) | |
Patients with primary infertility (n = 36) | 2471.54 (±4670.41) | 1062 (55.55–20,360) | 0.49 |
Patients with secondary infertility (n = 11) | 778.94 (±680.48) | 387.5 (106.7–2280) | |
Endometriosis patients with infertility (n = 28) | 1897.71 (±4065.21) | 702.35 (55.55–20,360) | 0.2 |
Endometriosis patients without infertility (n = 19) | 1022.88 (±2290.97) | 213.2 (98.95–10,180) | |
Non-endometriosis patients with infertility (n = 19) | 2337.25 (±4370.53) | 1076 (90.71–15,390) | 0.16 |
Non-endometriosis patients without infertility (n = 18) | 729.13 (±861) | 208.95 (27.17–2357) | |
Peritoneal fluid PARP concentrations [ng/L] | |||
Patients with infertility (n = 49) | 817.12 (±701.53) | 371.5 (12.55–2391) | 0.057 |
Patients without infertility (n = 35) | 563.8 (±582.48) | 267.8 (126.6–2219) | |
Patients with primary infertility (n = 39) | 833.96 (±700.86) | 371.5 (12.55–2219) | 0.74 |
Patients with secondary infertility (n = 10) | 751.46 (±738.13) | 393.05 (170.3–2391) | |
Endometriosis patients with infertility (n = 17) | 536.91 (±522.44) | 278.1 (12.55–2219) | 0.1 |
Endometriosis patients without infertility (n = 31) | 882.65 (±726.81) | 646.6 (126.9–1906) | |
Non-endometriosis patients with infertility (n = 18) | 704.26 (±660.36) | 311.5 (170.3–2391) | 0.26 |
Non-endometriosis patients without infertility (n = 36) | 646.73 (±647.56) | 294.15 (126.6–2219) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kacperczyk-Bartnik, J.; Bartnik, P.; Goławski, K.; Sierdziński, J.; Mańka, G.; Kiecka, M.; Lipa, M.; Warzecha, D.; Spaczyński, R.; Piekarski, P.; et al. Plasma and Peritoneal Poly (ADP-Ribose) Polymerase Levels in Patients with Endometriosis. Biomedicines 2022, 10, 2451. https://doi.org/10.3390/biomedicines10102451
Kacperczyk-Bartnik J, Bartnik P, Goławski K, Sierdziński J, Mańka G, Kiecka M, Lipa M, Warzecha D, Spaczyński R, Piekarski P, et al. Plasma and Peritoneal Poly (ADP-Ribose) Polymerase Levels in Patients with Endometriosis. Biomedicines. 2022; 10(10):2451. https://doi.org/10.3390/biomedicines10102451
Chicago/Turabian StyleKacperczyk-Bartnik, Joanna, Paweł Bartnik, Ksawery Goławski, Janusz Sierdziński, Grzegorz Mańka, Mariusz Kiecka, Michał Lipa, Damian Warzecha, Robert Spaczyński, Piotr Piekarski, and et al. 2022. "Plasma and Peritoneal Poly (ADP-Ribose) Polymerase Levels in Patients with Endometriosis" Biomedicines 10, no. 10: 2451. https://doi.org/10.3390/biomedicines10102451